Private Banking|Professional Solutions|Investment Management|Investment Banking|About us
  • Solutions
  • Sectors
  • Careers
Nov 2013
DBV 2 logo
Joint Bookrunner
€ 29.9 million
Additional Fundraise


DBV Technologies is a French biotech company, whose lead product is a patch for the treatment of peanut allergy

  • DBV raised additional funding to finance its development strategy, while the transaction also allowed long-term holders to monetize part of their stakes.
  • Kempen & Co acted as Joint Bookrunner and placed 80% of the shares with US investors.

Fully focused on your future

Private Banking
  • Offices
  • Entrepreneurs
  • Healthcare
  • Executives
  • Business professionals
  • Wealth management
  • Conditions
  • Private Banking - Belgium
  • Private Banking - Switzerland

Professional Solutions
Investment Management
Investment Banking

© Van Lanschot Kempen NV 2024About usSecurity and fraud awarenessPrivacy & cookiesDisclaimer